YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors. This follows the recent...
MILPITAS, Calif.–(BUSINESS WIRE)– Silicon Valley-based medical device company PQ Bypass announced today the 100th patient in the DETOUR2 Clinical Trial, which evaluates the safety and effectiveness of the minimally invasive DETOUR procedure for...
Medigene dendritic cell vaccine presents the antigens WT-1 and PRAME January 11th, 2020 – A Munich based immuno-oncology company published topline results from its completed open-label Phase I/II clinical trial of Medigene’s autologous dendritic cell (DC)...
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in...
Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing...
Email
Text